Yi-Hsien Hsieh

Dr. Yi-Hsien Hsieh

Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CWChih-Hung Wang
Chih-Hung Wang
Yi-Hsien HsiehYi-Hsien Hsieh
Yi-Hsien Hsieh
ZPZachary Powers
Zachary Powers
Cheng-Yen KaoCheng-Yen Kao
Cheng-Yen Kao
Antibiotics are one of the greatest medical advances of the 20th century, however, they are quickly becoming useless due to antibiotic resistance that has been augmented by poor antibiotic stewardship and a void in novel antibiotic discovery. Few novel classes of antibiotics have been discovered since 1960, and the pipeline of antibiotics under development is limited. We therefore are heading for a post-antibiotic era in which common infections become untreatable and once again deadly. There is thus an emergent need for both novel classes of antibiotics and novel approaches to treatment, including the repurposing of existing drugs or preclinical compounds and expanded implementation of combination therapies. In this review, we highlight to utilize alternative drug targets/therapies such as combinational therapy, anti-regulator, anti-signal transduction, anti-virulence, anti-toxin, engineered bacteriophages, and microbiome, to defeat antibiotic-resistant bacteria.

31 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
JTJen-Pi Tsai
Jen-Pi Tsai
CLChien-Hsing Lee
Chien-Hsing Lee
TYTsung-Ho Ying
Tsung-Ho Ying
CLChu-Liang Lin
Chu-Liang Lin
CLChia-Liang Lin
Chia-Liang Lin
Yi-Hsien HsiehYi-Hsien Hsieh
Yi-Hsien Hsieh
Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells

1 October 2011 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
TYTsung-Ho Ying
Tsung-Ho Ying
SYShun-Fa Yang
Shun-Fa Yang
STSu-Ju Tsai
Su-Ju Tsai
SHShu-Ching Hsieh
Shu-Ching Hsieh
YHYi-Chang Huang
Yi-Chang Huang
Yi-Hsien HsiehYi-Hsien Hsieh
Yi-Hsien Hsieh

5 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRuey-Hwang Chou
Ruey-Hwang Chou
SHShu-Ching Hsieh
Shu-Ching Hsieh
YYYung-Luen Yu
Yung-Luen Yu
MHMin-Hsien Huang
Min-Hsien Huang
YHYi-Chang Huang
Yi-Chang Huang
Yi-Hsien HsiehYi-Hsien Hsieh
Yi-Hsien Hsieh
Fisetin (3,3’,4’,7-tetrahydroxyflavone), a naturally occurring flavonoid, has been reported to inhibit proliferation and induce apoptosis in several cancer types. However, its effect on the anti-metastatic potential of cervical cancer cells remains unclear. In the present study, we found that fisetin inhibits the invasion and migration of cervical cancer cells. The expression and activity of urokinase plasminogen activator (uPA) was significantly suppressed by fisetin in a dose-dependent manner. We also demonstrated that fisetin reduces the phosphorylation of p38 MAPK, but not that of ERK1/2, JNK1/2, or AKT. Addition of a p38 MAPK inhibitor, SB203580, further enhanced the inhibitory effect of fisetin on the expression and activity of uPA and the invasion and motility in cervical cancer cells. Fisetin suppressed the TPA (tetradecanoylphorbol-13-acetate)-induced activation of p38 MAPK and uPA, and inhibited the TPA-enhanced migratory and invasive abilities. Furthermore, the promoter activity of the uPA gene was dramatically repressed by fisetin, which disrupted the nuclear translocation of NF-κB and its binding amount on the promoter of the uPA gene, and these suppressive effects could be further enhanced by SB203580. This study provides strong evidence for the molecular mechanism of fisetin in inhibiting the aggressive phenotypes by repression of uPA via interruption of p38 MAPK-dependent NF-κB signaling pathway in cervical cancer cells and thus contributes insight to the potential of using fisetin as a therapeutic strategy against cervical cancer by inhibiting migration and invasion.

7 September 2016 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
HHHsin‐Yu Ho
Hsin‐Yu Ho
CLChiao‐Wen Lin
Chiao‐Wen Lin
MCMing‐Hsien Chien
Ming‐Hsien Chien
RRRussel J. Reiter
Russel J. Reiter
SSShih‐Chi Su
Shih‐Chi Su
Shun-Fa YangShun-Fa Yang
Shun-Fa Yang

7 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CYChao-Bin Yeh
Chao-Bin Yeh
Ming-Ju HsiehMing-Ju Hsieh
Ming-Ju Hsieh
Yi-Hsien HsiehYi-Hsien Hsieh
Yi-Hsien Hsieh
MCMing-Hsien Chien
Ming-Hsien Chien
HCHui-ling Chiou
Hui-ling Chiou
Shun-Fa YangShun-Fa Yang
Shun-Fa Yang
The rate of morbidity and mortality of hepatocellular carcinoma (HCC) in Taiwan has not lessened because of difficulty in treating tumor metastasis. Norcantharidin (NCTD) is currently used as an anticancer drug for hepatoma, breast cancer, and colorectal adenocarcinoma. NCTD possesses various biological anticancer activities, including apoptosis. However, detailed effects and molecular mechanisms of NCTD on metastasis are unclear. Thus, HCC cells were subjected to treatment with NCTD and then analyzed to determine the effects of NCTD on cell metastasis. Modified Boyden chamber assays revealed that NCTD treatment inhibited cell migration and invasion capacities of HCC cells substantially. Results of zymography and western blotting showed that activities and protein levels of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (u-PA) were inhibited by NCTD. Western blot analysis showed that NCTD inhibits phosphorylation of ERK1/2. Testing of mRNA level, quantitative real-time PCR, and promoter assays evaluated the inhibitory effects of NCTD on MMP-9 and u-PA expression in HCC cells. The chromatin immunoprecipitation (ChIP) assay for analyzing the genomic DNA sequences bound to these proteins was reactive to the transcription protein nuclear factor (NF)-kappaB, which was inhibited by NCTD. The expression of NF-kappa B was measured by western blot analysis, which revealed decreased nuclear-factor DNA-binding activity after NCTD treatment. NCTD inhibited MMP-9 and u-PA expression through the phosphorylation of ERK1/2 and NF-kappaB signaling pathway which serves as a powerful chemopreventive agent in HCC cell metastasis.